Last Updated : April 25, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Akeega | niraparib abiraterone acetate | Metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Active | ||
N/A | everolimus | Renal angiomyolipoma associated with tuberous sclerosis complex | Reimburse with clinical criteria and/or conditions | Active | ||
Awiqli | insulin icodec | Diabetes mellitus, type 2 | Active | |||
Epidiolex | cannabidiol | Seizures associated with Tuberous Sclerosis Complex (TSC) | Active | |||
Epidiolex | cannabidiol | Dravet Syndrome (DS) | Active | |||
Epidiolex | cannabidiol | Lennox-Gastaut Syndrome (LGS) | Active | |||
Bimzelx | bimekizumab | Psoriatic arthritis | Active | |||
Bimzelx | bimekizumab | Ankylosing spondylitis | Active | |||
Vraylar | cariprazine | Schizophrenia | Active | |||
Hemgenix | etranacogene dezaparvovec | Hemophilia B | Active |